Know Diabetes by Heart: The American Diabetes Association’s 83rd Scientific Sessions Recap |
![]() |
Drs. Aroda, Benson, Bjornstad and Taveira discussed clinical highlights from the 2023 Scientific Sessions related to cardiovascular disease (CVD) and renal risk management and how to apply these relevant highlights to improve patient outcomes. For more information on treating people with type 2 diabetes and CVD visit: KnowDiabetesbyHeart.org/Professional
00:00 - Introduction 02:19 - Updates in ADA’s Standards of Care in Diabetes—2023 07:39 - Outcomes for Primary Prevention Patients in the CLEAR Outcomes Trial 14:13 - Improving Outcomes for Adolescents with Type 2 Diabetes 18:19 - Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Trial Results 24:27 - Kelly West Award for Outstanding Achievement in Epidemiology—Diabetes in South Asians—Uncovering Novel Risk Factors with Longitudinal Epidemiologic Data 29:00 - SGLT2i and GLP-1RA in Cardiovascular Disease—An Update for Clinical Practice in 2023 35:56 - Beyond Antihyperglycemic and Antihypertensive Agents for Diabetic Kidney Disease 40:55 - Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes— Results from OASIS 1 and PIONEER PLUS Trials 44:26 - Question & Answer |